Minimal residual diseases (MRD) are small amounts of cancer cells that may remain in a patient's body after treatment. MRD testing is studied in leukemia, lymphoma, and solid tumors. MRD testing is usually performed by advanced technologies such as flow cytometry, PCR-based assays, or next-generation sequencing to detect circulating tumor DNA (ctDNA) in the blood or microscopic tumor cells in the bone marrow of cancer patients. It is widely used for monitoring the efficacy of cancer patients, assessing the risk of recurrence, evaluating prognosis and making decisions about therapeutic interventions.
CD Genomics offers reliable MRD reference products to help you conduct solid tumor (lung, colorectal, breast, prostate, etc.) studies to further guide treatment decisions and assess patients' risk of recurrence.
MRD testing in solid tumors is challenging due to the large individual variation in solid tumors and the extremely low levels of ctDNA released into peripheral blood from early stage tumors. We develop accurate MRD reference products for process performance validation and routine quality control of MRD laboratory testing programs. These reference products require the highest level of NGS panel design and sensitivity for MRD detection.
Our MRD reference products are derived from 100% cell lines.
Our MRD reference products are widely used in MRD labs for process performance validation and daily quality control.
Explore Our Minimal Residual Disease (MRD) Reference Products:
|Cat. No.||Product Name||Brief Description||Inquiry||Basket|
|MRDR001||CD Tumor Micro-Residue Lesion Detection ctDNA Quality Control Kit||To facilitate the clinical application and promotion of the MRD LDT process for solid tumors, CD has developed a ctDNA quality control product suitable for performance validation and daily quality control of the MRD LDT process.|